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Abstract
Metabolomic profiling of prostate cancer (PCa) progression identified markedly elevated levels of sarcosine
(N-methyl glycine) in metastatic PCa and modest but significant elevation of the metabolite in PCa urine. Here,
we examine the role of key enzymes associated with sarcosine metabolism in PCa progression. Consistent with
our earlier report, sarcosine levels were significantly elevated in PCa urine sediments compared to controls, with a
modest area under the receiver operating characteristic curve of 0.71. In addition, the expression of sarcosine
biosynthetic enzyme, glycine N-methyltransferase (GNMT), was elevated in PCa tissues, while sarcosine dehydro-
genase (SARDH) and pipecolic acid oxidase (PIPOX), which metabolize sarcosine, were reduced in prostate
tumors. Consistent with this, GNMT promoted the oncogenic potential of prostate cells by facilitating sarcosine
production, while SARDH and PIPOX reduced the oncogenic potential of prostate cells by metabolizing sarcosine.
Accordingly, addition of sarcosine, but not glycine or alanine, induced invasion and intravasation in an in vivo PCa
model. In contrast, GNMT knockdown or SARDH overexpression in PCa xenografts inhibited tumor growth. Taken
together, these studies substantiate the role of sarcosine in PCa progression.
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Introduction
Prostate cancer (PCa) afflicts one in nine men over the age of 65 and
represents the most commonly diagnosed cancer in American men
[1]. Although radiation and surgery are generally effective for the
majority of men, prognosis remains poor in patients with progressive
disease. A distinct set of genes, proteins, and metabolites orchestrates
cancer progression from precursor lesion to localized disease and
finally to metastatic cancer [2]. Although gene and protein expression
profiles have been extensively studied in PCa, little is known about
the global metabolomic alterations. Disease-specific metabolites
represent the effective end points of the molecular pathways that are
initiated at genomic, transcriptomic, and proteomic levels [3] and may
serve as valuable biomarkers.
In our initial study [4], we profiled approximately 1126 metabolites
across 262 prostate-derived clinical samples and found that levels of
sarcosine, an N-methyl derivative of the amino acid glycine, increased
progressively in benign, localized PCa and metastatic disease. Sub-
sequent studies from Jentzmik et al. confirmed elevated levels of tissue-
associated sarcosine in prostate tumors compared to benign prostate [5].
In addition, our profiling study also reported elevated sarcosine levels in
post-digital rectal examination (DRE) urine specimens (sediment and
supernatant) from biopsy-positive PCa patients compared to biopsy-
negative controls, with an area under curve (AUC) of 0.67. On the basis
of this modest discriminatory power, we had nominated sarcosine as a
candidate for validation and as a potential marker for inclusion into
a multiplex biomarker panel for PCa detection. Since then, multiple
cross-institutional validation studies to evaluate the discriminatory
power of urinary sarcosine have been carried out [6–8]. Importantly,
the three major studies that have used at least 50 or more samples
in their validation efforts reported identical AUC for sarcosine in the
range of 0.65 to 0.68 confirming our published results [6–8]. In all
of these cases, sarcosine performs modestly better than serum prostate-
specific antigen (PSA) in detecting biopsy-positive PCa in a clinically
challenging PSA range of 4 to 10 ng/ml, while the free/total PSA ratio
(%fPSA), when used as a measure, was shown to be a better predictor
in the European study [9]. Furthermore, when used in amultiplex setting,
sarcosine improved the overall AUC of a multiplex biomarker panel [7],
consistent with our initial prediction. A recent study in individuals with
serum PSA levels < 4 ng/ml demonstrated a higher predictive value for
serum-associated sarcosine in detecting PCa compared to total PSA or
% fPSA [10]. Within this nested PSA-controlled subset, serum sarcosine
levels were significantly higher in patients with high-grade tumors. This
diagnostic ability for sarcosinewas also evident in yet another independent
study that reported significantly elevated levels of the metabolite in pre-
surgical urine specimens of PCa patients who developed early biochemical
recurrence [11]. Together, these findings substantiate our published data
describing sarcosine as an oncometabolite in PCa [4]. In addition to high-
lighting its ability to detect PCa, here we characterize the role of sarcosine
in modulating the tumorigenic properties of PCa cells in vitro. Further,
we used an independent cohort of clinical samples to validate the modest
potential of sarcosine to detect PCa at biopsy and characterized the onco-
genic potential of the metabolite in a xenograft model.
An overview of the sarcosine pathway is shown in Figure 1A.
The major enzymes regulating sarcosine metabolism are glycine
N -methyltransferase (GNMT), sarcosine dehydrogenase (SARDH),
and L-pipecolic acid oxidase (PIPOX). In cells, sarcosine (N -methyl
glycine) is generated by the enzymatic transfer of a methyl group from
S -adenosylmethionine (SAM) to glycine with the concomitant pro-
duction of S -adenosylhomocysteine (SAH). This reaction is catalyzed
by the enzyme GNMT that is expressed at high levels in mammalian
Figure 1. Levels of sarcosine and its pathway enzymes in PCa progression. (A) Schematic representation of the sarcosine pathway and
its potential role in PCa. (B) Receiver operating characteristic curve for sarcosine in the 345 urine sediments from 211 biopsy-positive and
134 biopsy-negative individuals. Sarcosine has an AUC of 0.71. (C) Box plot showing significantly (P< .0001) higher levels of sarcosine relative
to alanine in urine sediments from biopsy-proven PCa and prostate biopsy–negative controls. (D) Box plot showing progressive elevation of
sarcosine during progression from benign to localized (PCa) to MET samples (benign vs PCa, P = .0006 and benign vs METS, P < .00001).
492 Role of Sarcosine in Prostate Cancer Progression Khan et al. Neoplasia Vol. 15, No. 5, 2013
liver, exocrine pancreas, and prostate [12,13] (Figure 1A). The
sarcosine-metabolizing enzymes, SARDH and PIPOX, catalyze the
oxidative demethylation of sarcosine converting it back to glycine
[14,15] (Figure 1A). Using both in vitro and in vivo preclinical models,
this study validates sarcosine as an oncometabolite in PCa.
Materials and Methods
Clinical Specimens and Processing
Benign prostate and localized PCa tissues were obtained from a radi-
cal prostatectomy series at the University of Michigan Hospitals; meta-
static PCa biospecimens (MET) were retrieved from the Rapid Autopsy
Program, both of which are part of the University of Michigan Prostate
Cancer Specialized Program of Research Excellence Tissue Core. Sam-
ples were collected with informed consent and prior Institutional Re-
view Board approval at the University of Michigan (Ann Arbor, MI).
Urine specimens were collected from patients screened in the urology
clinic for PCa. The median age of these patients was 62.57 ± 8.14, who
had clinically significant levels of PSA (8.59 ± 6.30). Urine was col-
lected post-DRE and before biopsy. In addition, urine from patients
undergoing prostatectomy, collected before surgery, was used as a
positive control. In total, 652 urine specimens were examined in this
study, which included 168 biopsy-negative, 261 biopsy-positive, and
210 radical retropubic prostatectomy (RRP) specimens. Six specimens
from individuals with high-grade prostatic intraepithelial neoplasia
(HGPIN) and seven samples from individuals with undetermined diagno-
sis were excluded from the study during data analysis. Further, as described
later, urine samples with an alanine ratio greater than 2.5 were also ex-
cluded from the analysis. Thus, overall 507 urine specimens were used to
examine the ability of sarcosine to distinguish PCa from controls at biopsy.
Frozen tissue, cell line pellets, or urine sediments were homogenized
in methanol after spiking with labeled internal standards (D3-sarcosine
for tissues and cell lines and D3-alanine and D3-sarcosine for urine
sediments) and extracted overnight at 4°C, with constant shaking.
The extraction was carried using 1:1 molar ratio of water/chloroform
at room temperature. The aqueous methanolic layer was collected and
dried completely. The dried methanolic extract was azeotroped twice
by adding 100 μl of dimethylformamide, mixed by vortexing, and
dried using a Speed Vac for 30 minutes. One hundred μl of dimethyl-
formamide and N -methyl-N -tert-butylmethylsilyltrifluoroacetamide +
1% t-butyl-dimethylchlorosilane were then added to the dried sam-
ple, capped, and incubated at 60°C for 1 hour. Following this,
the sample was resuspended in ethyl acetate and injected into a gas
chromatograph–mass spectrometer. Selective ion monitoring was used
for quantification. Importantly, both these metabolites were baseline
separated before their quantification. The amount of sarcosine and
alanine in the sample was calculated by measuring the peak area of
the native sarcosine and alanine (both having m/z = 232) to that cor-
responding to spiked isotope-labeled sarcosine and alanine (both m/z =
235; Figure W1, A and B), as described in our previous study [4].
Following this, for tissues, the level of sarcosine was normalized to
the tissue weight. In case of urine sediments, a ratio of normalized
sarcosine to normalized alanine was derived. Urine specimens having
normalized alanine levels (m/z = 232/235) > 2.5-fold were removed
and not used for further analysis. This resulted in a total of 134 biopsy-
negative, 211 biopsy-positive, and 162 RRP samples that were used
to evaluate the biomarker potential of sarcosine. To evaluate the accu-
racy and limit/linearity of detection of sarcosine, we performed rep-
licate experiments (technical and biologic) as well as developed a
calibration curve for the metabolite in urine sediments (Figure W2,
A and B, calibration curve for alanine and sarcosine and Figure W2,
C and D, technical and biologic replicate measurements).
Plasmids, Cell Lines, and Cell Culture
Mammalian expression construct of SARDH and PIPOX were
generated by subcloning the polymerase chain reaction (PCR) product
into the pEF vector usingNot1 and Xba1 sites. Full-length GNMT was
cloned in lentiviral vector backbone FUGW (kindly gifted by David
Baltimore Laboratory, Pasadena, CA) and virus generated for further
transduction. The primers used are listed in Table W1. The benign
immortalized prostate cell line RWPE and PCa cell lines DU145,
PC3, and LNCaP were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). DU145, LNCaP, and PC3 PCa
cells were cultured in RPMI supplemented with 10% FBS (Invitrogen,
Carlsbad, CA). RWPE cells were grown in keratinocyte serum-free me-
dium (Invitrogen) supplemented with 5 ng/ml human recombinant
epidermal growth factor and 0.05 mg/ml bovine pituitary extract. All
the cells used in this study were tested for mycoplasma using a PCR-
based method (Lonza, Norwalk, CT). For stable knockdown of
GNMT, SARDH, or PIPOX, human lentiviral shRNA clones target-
ing the respective gene or nonsilencing (control) lentiviral shRNA in
pLKO puromycin vectors were purchased from Sigma (St Louis,
MO). Viral particle infections were carried out in the presence of poly-
brene (8 μg/ml) in 50% to 60% confluent DU145 and RWPE cells.
After 48 hours, transduced cells were grown in DU145 and RWPE
culture media containing puromycin (2 μg/ml). Three weeks later, sta-
ble cells were plated into 96-well plate for clonal selection. GNMT,
SARDH, and PIPOX knockdown were confirmed in pooled and single
clones by quantitative PCR (qPCR) and individual clones showing
highest levels of knockdown were further expanded. For overexpression
studies, stable cell lines were created by transfecting the FLAG-SARDH
and FLAG-PIPOX construct and vector control into DU145 cells
using FuGENE 6 (Roche, Indianapolis, IN) and resulting clones were
selected using 300 μg/ml G418 (Invitrogen).
Immunoblot Analysis and Antibodies
Protein extracts were prepared from benign prostate, localized PCa,
and metastatic tumor tissues, and standard immunoblot analysis was
performed. Briefly, prostate tissues were homogenized in NP-40 lysis
buffer containing 50 mM Tris-HCl (pH 7.4), 1% NP-40 (Sigma),
and complete protease inhibitor cocktail (Roche). Fifteen micrograms
of protein extract was mixed with sodium dodecyl sulfate sample buffer
and run on a 4% to 12% Bis-Tris gel under reducing conditions. The
separated proteins were transferred onto polyvinylidene fluoride mem-
branes (Amersham Pharmacia Biotech, Piscataway, NJ) and incubated
for 1 hour in blocking buffer (Tris-buffered saline with 0.1% Tween
and 5% nonfat dry milk), followed by incubation with the appropriate
primary antibodies overnight at 4°C. After washing with Tris-buffered
saline with 0.1% Tween buffer, the membrane was incubated with
HRP-linked donkey, anti-rabbit IgG antibody (GE Healthcare Life
Sciences, Piscataway, NJ) at 1:5000 for 1 hour at room temperature.
Specific signals were visualized by using ECL Plus Western Detection
System (GE Healthcare Life Sciences). The anti-FLAG (M2) antibody
was obtained from Sigma-Aldrich (St Louis, MO). Antibody against
GNMT (H-225) was acquired from Santa Cruz Biotechnology (Santa
Cruz, CA). SARDH and PIPOX antibodies were obtained from Aviva
Systems Biology (San Diego, CA) and Abnova (Taipei, Taiwan), respec-
tively. Antibody for poly(ADP-ribose) polymerase (PARP) was purchased
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from Cell Signaling Technology (Danvers, MA). The anti–β-actin
antibody was purchased from Abcam (Cambridge, MA). Protein lev-
els for actin were used as loading control.
Quantitative PCR
Total RNA was isolated from DU145-shNS–, DU145-shGNMT–,
RWPE-shNS–, RWPE-shSARDH–, or RWPE-shPIPOX–transduced
cells (Qiagen, Gaithersburg, MD). qPCR was performed using SYBR
Green dye on the StepOne Real-Time PCR System (Applied Biosystems,
Foster City, CA) [16]. Briefly, 1 μg of total RNA was reverse transcribed
into cDNA using SuperScript III (Invitrogen) in the presence of random
primers (Invitrogen). All reactions were performed in triplicates with
SYBR Green Master Mix (Applied Biosystems) and 25 ng of both the
forward and reverse primers according to the manufacturer’s recom-
mended thermocycling conditions and then subjected to melt curve anal-
ysis. Threshold levels for each experiment were set during the exponential
phase of the qPCR reaction using Sequence Detection Software version
1.2.2 (Applied Biosystems). The relative quantity of the target gene
was computed for each sample using the ΔΔC t method by comparing-
mean C t of the gene to the mean C t of the housekeeping gene,
glyceraldehyde 3-phospate dehydrogenase (GAPDH ) [17]. All oligonucleotide
primers were synthesized by Integrated DNA Technologies (Coralville,
IA). Sequences of all primers used in qPCR analyses are listed in TableW1.
Flow Cytometry Analysis
shGNMT-DU145 cells were collected and fixed with 5 ml of
ice-cold methanol for 1 hour at 4°C. Fixed cells were resuspended in
phosphate-buffered saline solution containing RNase and propidium
iodide (200 μg/ml; Sigma), and flow cytometry analysis was performed.
Cell cycle profiles were obtained using a BD Biosciences FACSCalibur
flow cytometer and CellQuest software. Apoptosis was assessed using
sub-G0/G1 DNA content.
Immunohistochemistry
A study pathologist (R.M.) reviewed the slides of all tissue samples
from the radical prostatectomy series and designated areas of interest.
These slides were used as a template for tissue microarray (TMA) con-
struction. All TMAs were assembled using the manual tissue arrayer
(Beecher Instruments, Silver Spring, MD) with at least three tissue cores
sampled from each donor block. Histologic diagnosis of the tissue cores
was verified by standard hematoxylin and eosin staining of the initial
TMA slide. Standard biotin-avidin complex immunohistochemistry
was performed using a polyclonal anti-GNMT antibody (Santa Cruz
Biotechnology). Digital images were acquired using the BLISS Imaging
System (Bacus Laboratory, Lombard, IL) and evaluated using a previously
validated web-based tool (TMA Profiler; University of Michigan) [18].
Staining was scored as negative (score = 1), weak (score = 2), moderate
(score = 3), or strong (score = 4) based on the intensity of staining of
tumor cells using a similar system that has been validated previously [19].
Cell Proliferation Assay
Cells were seeded in 24-well plates. Cell counts were estimated by
trypsinizing cells and analyses by Coulter Counter (Beckman Coulter,
Fullerton, CA) at the indicated time points in triplicate.
Basement Membrane Matrix Invasion Assay
For invasion assays, shNS vector or shGNMT-transduced DU145
cells, shSARDH- or shPIPOX-transduced RWPE cells, and RWPE
and DU145 cells were used. Briefly, warm serum-free medium was
mixed with Matrigel (Fisher Scientific, Waltham, MA) at 1:3 ratio;
100 μl of the Matrigel mixture was added into the center of each cell
well inserts of the Chemicon 24-well plate (Chemicon, Temecula, CA)
and allowed to solidify at room temperature for 3 to 4 hours. Cells were
trypsinized and resuspended in serum-free medium. In each insert,
approximately 1 × 105 cells in 100 μl of serum-free medium were placed
in the upper chamber and 500 μl of full medium with FBS was added
to the lower chamber as a chemoattractant. Cells were then grown in
the upper chamber for 48 hours. The noninvading cells inside the insert
were removed using a cotton swab and the inserts were stained for invaded
cells on the lower surface of the membrane. Invaded cells were stained
with crystal violet and photographed. The inserts were treated with
10% acetic acid, and absorbance was measured at 560 nm. Cell prolifera-
tion and invasion assays were performed as described [20–22].
Soft Agar Colony Assay
Fifty microliters of base layer of agar (0.6% agar in Dulbecco’s
modified Eagle’s medium with 10% FBS) was allowed to solidify in
a 96-well flat-bottom plate before the addition of 75 μl of suspension
of stable knockdown cells (shNS vector control, DU145-shGNMT,
RWPE-shSARDH, or RWPE-shPIPOX) containing 4000 cells in
0.4% agar in Dulbecco’s modified Eagle’s medium with 10% FBS.
The cell-containing layer was then solidified at 4°C for 15 minutes
before the addition of 100 μl of minimum essential medium (MEM)
with 5% FBS. Colonies were allowed to grow for 21 days before imag-
ing under a light microscope.
Chicken Chorioallantoic Membrane Assay
Briefly, fertilized eggs were incubated in a rotary humidified incuba-
tor at 38°C for 10 days. Chicken chorioallantoic membrane (CAM)
was released by applying mild amount of low pressure to the hole over
the air sac and cutting a square 1-cm2 window encompassing a second
hole near the allantoic vein. Cultured DU145 cells were transduced
with shGNMT virus, or FLAG-SARDH overexpressing cells were
detached by trypsinization and resuspended in complete medium
before implantation adjacent to the mesenchyme in each egg. Similarly,
2 million RWPE cells were pretreated with vehicle, sarcosine, alanine,
or glycine and applied to the upper CAM of a fertilized chicken
embryo. Cells used in the invasion assays were labeled with red fluores-
cent protein and processed as previously described [23]. The windows
were subsequently sealed and the eggs were returned to a stationary
incubator. For invasion and intravasation experiments, the upper or
lower CAM was isolated after 72 hours, respectively. For tumor growth
and metastasis, the eggs were incubated for 18 days in total, after which
the extraembryonic tumor were exercised and weighed, and the
embryonic liver were harvested and analyzed for the presence of tumor
cells by quantitative human Alu-specific PCR. Genomic DNA from
lower CAM and liver was prepared using Puregene DNA purification
system (Qiagen). Quantification of human cells in the extracted
DNA was performed as described [24]. Fluorogenic TaqMan qPCR
probes were applied as above and DNA copy numbers were quantified.
Prostate Tumor Xenograft Models
Five-week-old male nude athymic BALB/c nu/nu mice (Charles
River Laboratory, Wilmington, MA) were used for xenograft studies.
Stable shNS and shGNMT cells (5 × 106), SARDH overexpressing cells
(5 × 106), or vector control cells (5 × 106) were resuspended in 100 μl
of phosphate-buffered saline with 20% Matrigel (BD Biosciences)
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and implanted subcutaneously into the left flank regions of the mice.
Growth in tumor volume was recorded weekly using digital calipers,
and tumor volumes were calculated using the formula (π/6)(L ×
W 2), where L is the length of tumor and W is the width. Tumor
growth inhibition was defined as percent decrease in the mean tumor
volume for shGNMT relative to shNS vector and SARDH over-
expressing cells relative to the vector control. All experimental pro-
cedures involving mice were approved by the University Committee
on Use and Care of Animals at the University of Michigan and conform
to their relevant regulatory standards.
Statistical Analysis
To examine the biomarker potential of sarcosine for PCa, a classifi-
catory model based on logistic regression was developed. Here, the
value of normalized sarcosine was used as the predictor variable, and
biopsy status, i.e., positive or negative, was used as the binary outcome
variable. The performance of the model was examined by using the area
under the receiver operating characteristic curve (AUROC). AUROC
was determined using a cross-validation approach, by partitioning the
specimens (n = 345, both biopsy positive and negative) equally into
training and testing groups. The cross-validation was carried out by
repeating this partitioning process 5000 times. The receiver operating
characteristic reflecting the mean AUROC across all the iterations along
with the associated 95% confidence band is shown in Figure 1B.
For the functional studies, all values are presented as means ± SEM.
The significant differences between the groups were analyzed by a
Student’s t test and a P value < .05 was considered significant.
Results
Sarcosine Levels Are Significantly Elevated in PCa
We reconfirmed our earlier results on the modest ability of sarcosine
to detect PCa at biopsy, using a training/testing approach, on in-
dependent sets of urine specimens. To build the training model, we
used 211 biopsy-positive and 134 biopsy-negative urine sediments,
Figure 2. GNMT, SARDH, and PIPOX mRNA and protein expression are dysregulated in PCa. (A) Quantitative SYBR Green reverse
transcription–PCR (qRT-PCR) assessment of GNMT, SARDH, and PIPOX expression in prostate tumor specimens. Expression was deter-
mined in a cohort of 12 benign adjacent prostate (benign), 14 localized PCa, and 14 metastatic PCa (MET) tissues. For qRT-PCR, expression
of target genes was normalized to the expression of the housekeeping gene, GAPDH. (B) Immunoblot analysis showing GNMT, SARDH,
and PIPOX expression in benign, PCA, and MET. The protein levels of actin were used as loading control. (C) Representative prostate tissue
sections stained with an antibody to GNMT. (Left) GNMT expression in benign tissue was observed primarily in cytoplasm (green arrow).
(Right) In clinically localized PCa, the expression of GNMT was increased in the cytoplasm (red arrow) compared to weak expression in
benign gland from the same sample (green arrow). (D) Box plot of GNMT product score across PCa progression.
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Figure 3. The role of the sarcosine-generating enzyme, GNMT, in prostate cell lines. (A) Benign immortalized prostate RWPE cells were
transducedwith GFP-GNMT lentivirus ormock or GFP control. Increased levels of sarcosine were found in GFP-GNMT lentivirus–transduced
RWPE cells compared to mock or GFP control. GNMT overexpression also increased invasion in RWPE cells asmeasured by Boyden cham-
ber Matrigel invasion assay. Representative photomicrographs showing cell invasion assay (top inset) are shown. (B) Cell proliferation assay
using pooled shGNMT, shGNMT clone 7, shGNMT clone 9, or shNS cells at the indicated time points showing decreased cell proliferation in
shGNMT knockdown cells. (C) shGNMTclone 7 and shGNMT clone 9 or shNSDU14 cells were plated for 48 hours. The amount of sub-G0/G1
cells was calculated using the CellQuest program for fluorescence-activated cell sorting (FACS). Cleavage of PARP by immunoblot assess-
ment is shown in the top inset. (D) Assessment of sarcosine levels by GC-MS showing decreased levels of sarcosine in shGNMT knockdown
cells compared to shNSvector. The invasionwasquantitatedbyabsorbance andcellswerephotographedafter invasion throughMatrigel and
stained with crystal violet (top inset). (E) Pooled shGNMT, shGNMT clone 7, or shGNMT clone 9 blocked anchorage-independent growth in
soft agar assay compared to shNS vector control. Representative photomicrographs showing soft agar (top inset) are shown. All experiments
were independently performed in triplicates. (F) Exogenous sarcosine or alaninewas spiked to shGNMT clone 7 or shGNMT clone 9 cells and
invasion assaywas performed. The addition of sarcosine resulted in the rescue of invasion phenotype in these GNMT knockdown cells. Data
shown in the figure represent means ± SEM. Asterisks indicate significant comparisons (P < .05, two-sided Student’s t test).
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collected post-DRE and pre-biopsy. Using a logistic regression model,
sarcosine was found to have a cross-validated AUROC of 0.71, for
distinguishing biopsy-positive patients from biopsy-negative controls
(Figure 1B), verifying our earlier findings [4]. Sarcosine levels were
found to be significantly higher in urine sediments (P < .0001; Fig-
ure 1C) derived from biopsy-positive PCa patients compared to biopsy-
negative controls. In addition, using a similar approach, the AUROC
for sarcosine to distinguish biopsy-negative controls from the combined
group consisting of biopsy-proven PCa as well as patients who under-
went RRP was 0.695 (Figure W3). Following this, we next verified
elevated sarcosine levels in localized PCa and metastatic tissues. Sarco-
sine levels were significantly elevated in localized PCa (n = 11) compared
to benign adjacent prostate samples (n = 11, P = .0006; Figure 1D).
The levels of the metabolite were even greater in metastatic samples
(n = 10) compared to localized PCa (P < .00001; Figure 1D). Interest-
ingly, during the course of these validations, we observed that the
metabolite levels in noncancer-containing tissues were sensitive to the
“field effect” generated by the adjacent tumor. Thus, as shown in
Figure W4, the levels of sarcosine were elevated and comparable in
both the site of metastatic tumor and the adjacent pathologically normal
tissue. The levels of the metabolite, however, were undetectable in the
benign tissues that were distant from the metastatic site in the same
patient (Figure W4).
Transcript and Protein Levels of GNMT, SARDH, and
PIPOX Are Dysregulated during PCa Progression
Having confirmed elevated levels of sarcosine in localized/metastatic
tissues as well as biopsy-positive urine sediments, we examined the role
of sarcosine in PCa development and progression. To this end, we
first measured the mRNA levels of the enzymes in the sarcosine path-
way that included GNMT, SARDH, and PIPOX in prostate tissues.
We carried out SYBR Green real-time qPCR on 12 benign prostates,
14 localized PCa, and 14 metastatic samples. Our results confirmed
Figure 4. The role of the sarcosine-degrading enzymes, SARDH and PIPOX, in prostate cell lines. (A) FLAG-SARDH and FLAG-PIPOX
overexpressing cells showed decreased levels of sarcosine and attenuated invasion in DU145 cells. The invasion was quantitated by
absorbance and cells were photographed after invasion through Matrigel and stained with crystal violet (top inset). (B) FLAG-SARDH and
FLAG-PIPOX were stably overexpressed in DU145 cells. Cell proliferation assay performed using pooled SARDH, SARDH clone 5, pooled
PIPOX, PIPOX clone 2, or vector control cells at the indicated time points showed decreased cell proliferation in SARDH but not PIPOX
overexpressing cells. (C) Pooled SARDH or SARDH clone 5 showed decreased number of colonies in soft agar compared to vector
control. (D) Same as in B but for shSARDH knockdown RWPE cells (clones 1 and 3) and shPIPOX knockdown RWPE cells (clones 1
and 2) or their respective shNS controls at the indicated time points. (E) Same as in A but for shSARDH and shPIPOX knockdown RWPE
cells compared to their respective shNS controls. (F) Same as in C but for shSARDH and shPIPOX knockdown RWPE cells compared to
their respective shNS controls.
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elevated transcript levels for GNMT (t test, P < .001; Figure 2A, left
panel ) and reduced mRNA expression for SARDH and PIPOX in
PCa and MET relative to benign prostate tissues (t test, P < .001; Fig-
ure 2A, middle and right panels). This expression profile was further
confirmed at the protein level using immunoblot analysis (Figure 2B).
In addition, tissue microarray–based analyses of GNMT protein ex-
pression in prostate tissues (23 benign, 56 PCa, and 6 MET) revealed
cytoplasmic staining that was very high in metastatic tissues and mod-
erate to strong in PCa, while being low to undetectable in benign
adjacent prostate tissue (t test, P < .001; Figure 2, C and D). These
results allude to a stepwise increase in levels of sarcosine, from be-
nign prostate tissue to localized PCa to metastatic disease, as reported
earlier [4].
Perturbation of Sarcosine-Generating Enzyme, GNMT,
Modulates Neoplastic Progression of Prostate Cell Lines
Our data thus far suggest an elevation of sarcosine metabolism in
PCa progression. Furthermore, our earlier results that were based on
transient knockdown of enzymes in the sarcosine pathway indicated
a tumor-promoting role for this metabolite in PCa. To explore this
further, we examined the effect of ectopic overexpression of GNMT in
benign prostate epithelial cells, RWPE. To achieve this, we transduced
these benign cells with a lentiviral construct expressing GNMT [or green
fluorescent protein (GFP) as control] and measured their sarcosine levels
as well as examined its effect on proliferation and invasive potential.
Overexpression of GNMT in RWPE cells elevated sarcosine levels
(Figure 3A) with concomitant increase in invasion (Figure 3A; P = .0009)
but had no effect on cell proliferation (Figure W5).
Subsequently, we carried out a stable knockdown of the enzyme in
DU145 PCa cells that are known to be invasive. Here, we used two
independent GNMT-specific shRNA (shGNMT), individually as well
as in a pooled format, along with nontargeted shRNA (shNS) as a con-
trol. In all of these instances, we observed >70% reduction in GNMT
expression both at the mRNA (Figure W6A) and protein levels (Fig-
ure W6B). This was concomitantly associated with a reduction in cell
proliferation compared to nontarget-transduced controls (54% and
60% reduction, respectively; Figure 3B). This was reflected in flow
cytometry data, which showed an increase in the sub-G1 fraction, in
the knockdown cells (Figure 3C). Furthermore, these cells also exhib-
ited a greater percentage of cell death, possibly due to apoptosis. To
confirm this, we evaluated PARP family of proteins that are known to
be cleaved during programmed cell death. As expected, cells in which
GNMT was knocked down showed higher levels of cleaved PARP
compared to controls (Figure 3C , top inset), suggestive of apoptosis,
as an additional mechanism leading to reduced cell numbers.
In addition to changes in cell numbers, GNMT knockdown cells also
showed >65% reduction in both invasion and anchorage-dependent
growth compared to nontarget-transduced controls, as assessed by
Boyden chamber Matrigel assay and soft agar colony-forming assay
(Figure 3, D, gray bars, and E ; P < .005 for both invasion and soft agar
assay). Notably, all of the above phenotypes in cells with reducedGNMT
expression were also associated with markedly lower levels of sarcosine
(Figure 3D, black bars). Consistent with this, addition of sarcosine to
these cells partially rescued their invasive properties, while addition of a
control metabolite alanine failed to rescue the invasive phenotype
(Figure 3F ; P < .05). Addition of exogenous sarcosine did not completely
rescue invasive phenotype of DU145 cells expressing low levels of
GNMT possibly because endogenous SARDH and PIPOX activity con-
verted sarcosine to glycine. This needs to be verified by flux analysis using
isotopically labeled sarcosine and the study of the kinetics of 13C incor-
poration into the breakdown products. Furthermore, we believe that
wild-type DU145 cells are highly invasive, and hence, addition of sarco-
sine to these cells may not show a significant increase in invasion. Similar
results were also obtained with LNCaP and PC3 (both PCa) cell lines
harboring GNMT knockdown but not RWPE (benign) cells
(Figures W7–W9), reconfirming the importance of the metabolite
in PCa.
A Functional Role for SARDH and PIPOX in PCa
Progression In Vitro
Next, we examined the effect of perturbing the enzyme machinery
that regulates the metabolism of sarcosine to glycine on the phenotype
of the prostate cell lines. As described earlier in Figure 1A, SARDH
Figure 5. The role of sarcosine in PCa growth in vivo. (A) CAM inva-
sion assay performed using RWPE cells transducedwith red fluores-
cent protein virus for visualization. After puromycin selection, cells
were treatedwith vehicle, sarcosine, glycine, or alanine as indicated.
Seventy-two hours after implantation, the upper CAM was har-
vested. Frozen sections were created and stained for hematoxylin
and eosin (left column), human-specific cytokeratin (immunohisto-
chemistry, middle column), or chicken-specific type IV collagen
(green immunofluorescence, right column). Arrowheads indicate
cells that invaded through the upper CAM. Representative images
are shown. Scale bars, 200 μM. (B) CAM intravasation assay per-
formed using RWPE cells treated with vehicle, sarcosine, glycine,
or alanine as indicated. Seventy-two hours after implantation, the
lower CAM was harvested. Total DNA was isolated from the lower
CAM, and qPCR was performed using human-specific Alu PCR
primers. Total cell number was determined by comparing to a stan-
dard curve derived by using known quantities of input RWPE cells.
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and PIPOX convert sarcosine back to glycine. First, we examined the
effect of SARDH and PIPOX overexpression on growth and invasive
potential of DU145 PCa cells (Figure W10). Notably, in case of
DU145 cells, overexpression of these enzymes markedly decreased sar-
cosine levels and attenuated invasion (Figure 4A), while only SARDH
overexpression reduced proliferation (Figure 4B). Consistent with this,
only overexpression of SARDH but not PIPOX reduced colony for-
mation in soft agar relative vector control (Figure 4C ). In contrast,
knockdown of SARDH in RWPE cells increased sarcosine levels and
resulted in increased proliferation (Figure 4D), invasion (Figure 4E),
Figure 6. The role of sarcosine pathway enzymes, GNMT and SARDH, in PCa growth in vivo. (A) CAM intravasation assay was performed
using shGNMT clone 7, SARDH clone 5, and vector control in DU145 cells. Number of intravasated DU145 cells and tumor weight was
decreased in both shGNMT and SARDH overexpressing xenografted cell lines compared to vector control. (B) Liver metastasis in chicken
embryos was assessed 8 days following implantation of either shGNMT clone 7 or SARDH clone 5 or vector control cells onto the
upper CAM. Total number of metastasized cells were quantified and found to be significantly decreased in both shGNMT and SARDH
overexpressing xenografted cell lines compared to vector control. (C) shGNMT (clones 7 and 9) decreased DU145 tumor growth in
mice. Means ± SEM are shown, *P< .05. (D) Stably overexpressed SARDH (pool and clone 5) decreased DU145 tumor growth in mice.
Means ± SEM are shown, *P < .05. (E) Box plots showing decreased sarcosine levels in shGNMT (clones 7 and 9) mouse xenograft
compared to shNS vector control. (F) Box plot showing decreased sarcosine levels in SARDH overexpressed (pool and clone 5) mouse
xenograft tumors compared to vector control.
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and anchorage-independent growth (Figure 4F ). However, knock-
down of PIPOX in RWPE increased sarcosine levels and made them
invasive, while having no effect on their proliferation and anchorage-
independent growth.
Sarcosine-mediated Invasion and Intravasation In Vivo
Further developing our in vitro findings, we examined the ability
of sarcosine, glycine, and alanine to trigger local invasion and intra-
vasation, in nontumorigenic RWPE cells, using a CAM assay [23].
Consistent with our in vitro data, addition of sarcosine but not glycine
or alanine induced invasion and intravasation in RWPE cells that
migrated across the upper CAM junction (Figure 5, A and B, arrows;
P < .01). GNMT knockdown or SARDH overexpression in DU145
PCa cells, however, resulted in a significant reduction in tumor weight
(P = .02 and P = .03, respectively) as well as decreased intravasation
(P = .01 for GNMT knockdown and P = .05 for SARDH overexpres-
sion, respectively; Figure 6A), and ability of the cells to metastasize
to the liver (P < .05), compared to controls (Figure 6B). Similar results
were obtained using PC3 PCa cells as shown in Figure W11.
To confirm these in vivo results further, we examined the effect of
GNMT knockdown and SARDH overexpression on in vivo tumor
growth using a mouse xenograft model. We implanted DU145 cells
containing either stable GNMT knockdown or ectopic overexpres-
sion of SARDH and their respective controls in nude male mice. At
5 weeks post-implantation, DU145 cells containing GNMT knock-
down formed significantly smaller tumors (∼75% reduction, P =
.0001) compared to control cells (Figure 6C). Similarly, SARDH over-
expressing tumors were also significantly reduced in size (∼70% reduc-
tion, P = .0001) compared to their corresponding controls (Figure 6D).
As expected, in both GNMT knockdown and SARDH overexpressing
tumors, sarcosine levels were significantly reduced compared to controls
(Figure 6, E and F ). Furthermore, the tumors containing GNMT
knockdown also had significantly elevated levels of SAM and lower
levels of SAH, indicative of reduced activity through the GNMT-
catalyzed reactome (Figure W12, A and B; P = .05).
Discussion
Our prior unbiased survey of the PCa metabolome identified sarco-
sine as a potential marker for aggressive disease that could be detected
noninvasively in urine [4]. Further, in vitro studies showed that exog-
enous addition of sarcosine induced an invasive phenotype in benign
prostate epithelial cells [4]. In the present study, we confirmed ele-
vated levels of sarcosine in PCa tissues and urine and establish a role
for sarcosine in promoting PCa growth and progression, using both
in vitro and in vivo models of the disease.
Our studies on tissues revealed that the levels of sarcosine in patho-
logically benign tissues could potentially be influenced by the presence
of an adjacent tumor. PCa like many tumors is known to exhibit a
“field effect” that influences the metabolism of adjacent benign tissues
[4,25]. Although the sensitivity of sarcosine levels to the underlying
“field effect” needs to be more extensively characterized, it could par-
tially explain the modest change in the metabolite levels seen in organ-
confined PCa compared to its matched benign adjacent tissues [4].
Irrespectively, our results confirm a progressive elevation in sarcosine
levels from benign adjacent tissue to localized tumors and metastatic
disease, nominating sarcosine as an oncometabolite in PCa.
In addition, here we also verified significantly elevated levels of the
metabolite in urine of biopsy-proven PCa patients compared to biopsy-
negative controls. The cross-validated AUROC of 0.71 that we ob-
tained for an independent cohort of more than 500 urine sediments
is comparable to the AUROC published by us and others [6–8].
Although, this amounts to a modest discriminatory power, we expect
sarcosine to be a useful biomarker in a multiplex setting. Studies
aimed at building such a multiplex panel containing sarcosine for
PCa detection are currently underway.
Further, to verify its role as an oncometabolite, we altered the levels
of sarcosine in prostate cell lines by modulating the expression of its
regulatory enzymes and examining the resulting phenotype, both in
in vitro and in vivo settings. Our results underscore the importance
of specific key enzymes associated with sarcosine metabolism, namely,
GNMT, SARDH, and PIPOX, in PCa progression. For example, both
the metabolite and its biosynthetic enzyme GNMT are elevated in
localized and metastatic PCa relative to benign tissues. Our present data
are supported by the work of Song et al. who indicate that PCa patients
with high GNMT cytoplasmic expression showed significantly lower
disease-free survival rates compared to patients with lower expression
levels of this enzyme [26]. We also acknowledge that these findings
are contrary to the results published by Huang et al., who reported loss
of a single GNMT copy in a significant proportion of human PCas,
leading to its lower expression in these tumors [27,28]. However,
our data on overexpression of GNMT are also supported by the obser-
vation of decreased levels of sarcosine-metabolizing enzymes SARDH
and PIPOX in PCa. Together, we believe, these findings portray ele-
vated flux toward sarcosine production in PCa, which is consistent
with its higher metabolite levels.
Mechanistically, elevated levels of sarcosine potentiate tumor pro-
gression by having a positive influence on proliferation, invasion,
and intravasation. Accordingly, GNMT knockdown or SARDH over-
expression in PCa cells attenuated tumor growth and metastasis, while
SARDH knockdown in benign epithelial cells promoted their prolif-
eration, invasion, and anchorage-independent growth. Intriguingly
however, an alteration in PIPOX expression affected only the invasive
property of the cells while having no bearing on their proliferation or
anchorage-independent growth. The reason for this disparity could be
that these enzymes have different subcellular localization and it is likely
that they distinctly affect downstream metabolism as potential deter-
minants for the observed differences in proliferation. Irrespective of
this, our data confirm SARDH as a potential tumor suppressor in
PCa, consistent with a recent report by Chen et al. [29]. In summary,
this study reiterates an important role for sarcosine in PCa progression
and highlights the potential of using the metabolite to develop a multi-
plex urine-based marker for PCa detection.
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Figure W1. (A) Extracted ion chromatogram of sarcosine and alanine in urine. (B) Selected ion monitoring of alanine and sarcosine.
Figure W2. Calibration curve of (A) alanine (B) sarcosine. (C and D) Reproducibility of sarcosine assessment using isotope dilution GC-MS.
Sarcosine measurement for 10 biopsy-positive and 10 biopsy-negative urine samples using two independent experiments was highly cor-
related with rho > 0.9. The horizontal and vertical axes represent the sarcosine/alanine ratio for the corresponding technical replicates
(runs 1 and 2) of the urine sediments. Values inside the boxes indicate the correlation (rho) for the given comparison with the 95% confi-
dence interval (CI) values in parenthesis.
Table W1. Sequence of Gene-Specific PCR Primers Used for Cloning and qPCR.
Gene-Specific Primer Primer Sequence
Not1–GNMT F 5′-TTTTCCTTTTGCGGCCGCgtggacagcgtgtaccggacc-3′
EcoR1–GNMT R 5′-CCGGAATTCtcagtctgtcctcttgagcac-3′
Not1–SARDH F 5′-TTTTCCTTTTGCGGCCGCgcctcactgagccgagcccta-3′
Xba1–SARDH R 5′-CTAGTCTAGAtcagtagattcccttcaccct-3′
Not1–PIPOX F 5′-TTTTCCTTTTGCGGCCGCgcggctcagaaagatctctg-3′
Xba1–PIPOX R 5′-CTAGTCTAGActaaaggtgggctttgcccaggct-3′
GNMT F* 5′-CTTCATCCACGTGCTCAAGA-3′
GNMT R* 5′-TCCCCATCTTCCAGACAGAG-3′
SARDH F* 5′-CTGATGAATGTGGACGACCT-3′
SARDH R* 5′-GTTCTCAATGACCTGTGCTC-3′
PIPOX F* 5′-CCTGTCTTTGCTTGCCTTTG-3′
PIPOX R* 5′-GAAGGGACACAGTACCTGCTC-3′
F and R stand for forward and reverse primers respectively.
*Denotes set of primers used for qPCR analysis.
Figure W4. Sarcosine levels inmetastatic and benign tissues of five different cancer patients. Sarcosine levels were found to be comparably
high in both metastatic tumor (black) and its matched adjacent pathologically benign tissues (gray), while still being undetectable in distal
nontumor tissues resected from the same patient [1].
Figure W3. AUROC for sarcosine in the 652 urine sediments from
168 biopsy-negative, 261 biopsy-positive, and 210 RRP individuals
was 0.695.
Figure W6. qRT-PCR and immunoblot analysis of GNMT knockdown in DU145 cells. (A) qPCR analysis of GNMT transcript in stable
shGNMT knockdown cells (stably selected pool and clones). (B) Western blot analysis showing stably puromycin-selected clones of
GNMT knockdown in DU145 cell model.
Figure W5. GNMT overexpression does not affect proliferation of
benign RWPE prostatic epithelial cells. The benign immortalized
prostate cell line RWPE was transduced for overexpression of
GNMT or GFP vector control. We observed no significant difference
in cell proliferation in RWPE-GNMT overexpressing cells relative to
either GFP transduced or mock.
Figure W7. Validation of GNMT knockdown followed by assessment of sarcosine levels in RWPE, PC3, and LNCaP cells. qPCR analysis
of GNMT transcript in stable shGNMT knockdown (A) RWPE, (B) PC3, and (C) LNCaP cells. Sarcosine levels were assessed by GC-MS in
stable shGNMT knockdown (D) RWPE, (E) PC3, and (F) LNCaP cells. We observed significant decrease in sarcosine levels after stable
GNMT knockdown in PC3 and LNCaP cells.
Figure W9. GNMT knockdown attenuates invasion in PC3 and LNCaP cells. (A) PC3 and (B) LNCaP cells were transduced with shGNMT,
or shNS vector control, stable cells were generated and assayed for cell invasion.
Figure W8. GNMT knockdown decreases cell proliferation in (A) PC3 and (B) LNCaP cells. GNMT knockdown in metastatic prostate
carcinoma (PC3) and androgen-responsive (LNCaP) cells resulted in the significant decrease in cell proliferation.
Figure W10. Validation of overexpression and knockdown of SARDH and PIPOX in DU145 and RWPE cells, respectively. (A) Western
blot showing stably transfected FLAG-tagged PIPOX and FLAG-tagged SARDH expression (pool and clones; DU145 cells). Actin was
used as loading control. qPCR analysis of RNA isolated in parallel to the invasion assay of (B) SARDH and (C) PIPOX.
Figure W11. Tumor weight decreases in GNMT knockdown PC3
xenografts in CAM assay compared to vector control.
Figure W12. Assessment of SAM and SAH in GNMT knockdown
mouse xenograft. (A) Box plot of SAM. (B) Box plot of SAH.
